UroGen Pharma (URGN) Misses Q4 EPS by 4c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
UroGen Pharma (URGN) PT Lowered to $34 at Oppenheimer
March 15, 2024 7:23 AM EDTOppenheimer analyst Leland Gershell lowered the price target on UroGen Pharma (NASDAQ: URGN) to $34.00 (from $35.00) while maintaining an Outperform rating.
The analyst commented, "4Q23 Jelmyto sales of $23.5M (+28% Y/Y) topped our $21.8M and consensus $22.6M estimates despite incremental 340B drug pricing impact on... More
